The case for & against
Bull & Bear analysis
Bearish
PROCEPT BioRobotics (NASDAQ: PRCT) is an emerging player in the medical technology sector, specializing in robotic-assisted surgical systems, particularly for the treatment of benign prostatic hyperplasia (BPH). The company holds a competitive edge through its proprietary surgical systems, which enhance precision and reduce recovery time for patients. PROCEPT operates within the rising trend of robotic surgery, aiming to capitalize on increasing demand for minimally invasive procedures in urology and beyond.
Bull says
- ↑Q1 revenue up 20.1% YoY; Q2 2026 guidance at $92.6M confirms growth
- ↑Robotic BPH system adoption rising, offering precision advantage over alternatives
- ↑Strong liquidity underpins R&D spend and operational runway despite losses
- ↑Analyst consensus target $33.45 implies ~65% upside from current levels
- ↑High growth factor signals expanding market share and improving metrics
- ↑Solid QS score reflects strong balance sheet; short interest hints at squeeze potential
Bear says
- ↓Projected Q2 2026 loss of $0.46 per share highlights ongoing unprofitability
- ↓Securities-fraud class actions triggered an 18% stock decline and legal risk
- ↓Negative leverage factor suggests high debt burden amid rising rates
- ↓Analysts rate PRCT as Hold/Neutral, signaling caution on outlook
- ↓Low institutional ownership warns of waning support and liquidity concerns
- ↓Weak margins, negative earnings yield cap valuation upside even with growth
Investment themes with PRCT
Medical Devices↓ -0.50%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 04-24-2025bullish
Transcript signals
Bull points
- Our goal is to treat men who have BPH. A lot of the impact, most of these men today are on medication, whether they go for resective or non-resective. So our goal is to treat all men and, yes, today, we get some of those patients who are wanted to get nonresective in a hospital setting. So we are not necessarily focusing that, are the patients for nonresective or resective, these are patients who are looking for long-term durability and efficacy on the procedure.
- There's a huge opportunity currently with the over 1 million men in the U.S. that have failed pharmaceuticals and have not done anything from a surgical option beyond that. We look at that as our ultimate opportunity. When we talk about market expansion, it's real. It's there in front of us, and so we don't necessarily say we're going to target to take this from one procedure or another. We're looking at BPH patients that have failed medications and taking those to the ASCs is a real opportunity for us.
- As we said, Sham and I, we said this is really about market expansion. Initially, yes, we started very thoughtfully with the high-volume centers of hospitals 860 up to 2,700. The data, as Kevin mentioned in 2019 was 300,000 resective procedures, but there are more than 12 million men with BPH and many failed to medication.
Bear points
- No, the short answer is no. We are not seeing that. In fact, we have started talking about the retirement of TPT more than a year ago, and the hospitals are buying our system for the clinical outcome and making the practice more efficient.
- about 10% of the 300,000 resective procedures were performed in the ASC, indicating limited current penetration in the ASC space.
Read full transcript analysis ›